Loading the section…

GPCR: financial statements from SEC — TradeAlmanac

GPCR

Structure Therapeutics Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Research and development	67M	59M	55M	43M	33M	22M
Selling, general and administrative	23M	15M	16M	13M	13M	11M
Operating expenses	89M	74M	70M	56M	46M	33M
Operating income	−89M	−74M	−70M	−56M	−46M	−33M
Pre-tax income	−76M	−66M	−62M	−47M	−34M	−26M
Income tax	190,000	108,000	139,000	98,000	92,000	53,000
Net income	−76M	−66M	−62M	−47M	−34M	−26M
Earnings per share	−0.35	−0.37	−0.36	−0.27	−0.20	−0.18
Earnings per share, diluted	−0.35	−0.37	—	−0.27	−0.20	−0.18
Weighted average shares	217M	175M	173M	172M	172M	148M
Weighted average shares, diluted	217M	175M	—	172M	172M	148M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	316M	800M	103M	147M	152M	170M	172M	382M
Short-term investments	1.14B	647M	696M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	15M	−52M
Depreciation and amortisation	576,000	274,000
Share-based compensation	12M	6M
Capital expenditure	1M	314,000
Investing cash flow	−497M	34M
Financing cash flow	−2M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator